Submission

AMA submission to the TGA on proposed scheduling changes to Finasteride and Sanguinarine

The AMA opposes the down-scheduling of Finasteride from Schedule 4 to Schedule 3 due to potential risks to patients. The AMA supports the proposal to classify Sanguinarine as a Schedule 10 medicine which would effectively prohibit its sale, supply and use in Australia.